netFormulary
 Report : Medicines with links to NICE 19/11/2018 22:51:00

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA 375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abatacept 10.01.03 Formulary NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Abiraterone acetate 08.03.04.02 Formulary NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Abiraterone acetate 08.03.04.02 Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Acetylcysteine (NAC) 03.11 Non Formulary NICE CG163: idiopathic pulmonary fibrosis diagnosis and management
Adalimumab 13.05.03 Formulary NICE TA146: Psoriasis - adalimumab
Adalimumab 13.05.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 01.05.03 Formulary NICE TA187: Crohn’s disease - infliximab (review) and adalimumab (review of TA40)
Adalimumab 01.05.03 Formulary NICE TA 329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
Adalimumab 10.01.03 Formulary NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Adalimumab 10.01.03 Formulary NICE TA 375 :Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Formulary NICE TA383 - Adalimumab, Etanercept and Infliximab for Ankylosing Spondylitis
Adefovir Dipivoxil 05.03.03.01 Non Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03.01 Non Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Afatinib 08.01.05 Formulary NICE TA310: Lung cancer (non small cell, EGFR mutation positive) - afatinib
Afatinib 08.01.05 Non Formulary NICE TA 452: Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)
Afatinib 08.01.05 Non Formulary NICE TA 444 Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)
Aflibercept 11.08.02 Formulary NICE TA 307 - Aflibercept in combination with Irinotecan and Fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Formulary NICE TA486: Aflibercept for treating choroidal neovascularisation
Aflibercept 11.08.02 Formulary NICE TA409 Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA294: aflibercept solution for injection for treating wet age-related macular degeneration
Aflibercept 11.08.02 Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA346 Aflibercept for treating diabetic macular oedema
Aflibercept 08.01 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Alectinib 08.01.05 Non Formulary NICE TA438: Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)
Alectinib 08.01.05 Formulary NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.04 Formulary NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alendronic Acid 06.06.02 Formulary NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Alendronic Acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Alendronic Acid 06.06.02 Formulary NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Alirocumab 02.12 Formulary NICE TA393 Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177: Eczema (chronic) - alitretinoin
Alteplase 02.10.02 Formulary NICE TA52: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Amantadine Hydrochloride 05.03.04 Formulary NICE TA158 Amantadine, oseltamivir and zanamivir for the treatment of influenza
Antithymocyte immunoglobulin (rabbit) 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Antithymocyte immunoglobulin (rabbit) 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Apixaban 02.08.02 Formulary NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
Apixaban 02.08.02 Formulary NICE TA341 Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Formulary NICE TA245: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apixaban 02.08.02 Formulary NICE TA 341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Formulary NICE TA 275: Apixaban for preventing stroke and systemic embolism in people with nonvalvular atrial fibrillation
Apixaban 02.08.02 Formulary NICE TA 245:Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apremilast 13.05.03 Formulary NICE TA419 Apremilast for treating moderate to severe plaque psoriasis
Apremilast 10.01.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis
Aripiprazole (oral) 04.02.01 Formulary NICE TA292: aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder
Aripiprazole (oral) 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Arsenic Trioxide 08.01.05 Formulary NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Atezolizumab 08.01.05 Formulary NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.01.05 Formulary NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (only in adults with high levels of PD-L1)
Atezolizumab 08.01.05 Formulary NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atomoxetine 04.04 Formulary NICE NG87: methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Avelumab 08.01.05 Formulary NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Avelumab 08.01.05 Formulary Managed Access Agreement: Avelumab for treating metastatic Merkel cell carcinoma
Axitinib 08.01.05 Formulary NICE TA 333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Azacitidine 08.01.03 Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azacitidine 08.01.03 Non Formulary NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Baricitinib 10.01.03 Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Basiliximab 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults (replaces TA85)
Basiliximab 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people (replaces TA99)
Belatacept 08.02.02 Non Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Belatacept 08.02.02 Non Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Belimumab 10.01.03 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia (CLL)
Bevacizumab 08.01.05 Non Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Bevacizumab 08.01.05 Non Formulary NICE TA178: Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma
Bevacizumab 08.01.05 Non Formulary Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer (TA118)
Bevacizumab 08.01.05 Non Formulary Bevacizumab for the treatment of non-small-cell lung cancer (terminated appraisal)
Bevacizumab 08.01.05 Non Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Non Formulary NICE TA436: Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer
Bevacizumab 08.01.05 Non Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Non Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bevacizumab 08.01.05 Non Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Non Formulary NICE TA212: Colorectal cancer (metastatic) - bevacizumab
Bivalirudin 02.08.01 Formulary NICE CG94: Unstable angina and NSTEMI
Bivalirudin 02.08.01 Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02.03 Formulary NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Bortezomib 08.01.05 Non Formulary NICE TA Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)
Bortezomib 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first-line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bosutinib 08.01.05 Formulary NICE TA401 Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.07.04.02 Formulary In accordance with NICE TA 260
Brentuximab vedotin 08.01.05 Formulary NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Formulary NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brodalumab 13.05.03 Formulary NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Bupropion 04.10.02 Formulary NICE PH45: tobacco: harm-reduction approaches to smoking.
Bupropion 04.10.02 Formulary NICE NG92 Stop smoking interventions and services
Cabazitaxel 08.01.05 Formulary NICE TA391 Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Formulary NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA516: Cabozantinib for treating medullary thyroid cancer
Canagliflozin 06.01.02.03 Formulary NICE TA 315 -Canagliflozin in combination therapy for treating type 2 diabetes
Canakinumab 08.02.04 Formulary NICE TA302: terminated TA on canakinumab for treating juvenile arthritis
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA61: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Carboplatin 08.01.05 Formulary Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Carboplatin 08.01.05 Formulary Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer (TA285)
Carfilzomib 08.01.05 Formulary NICE TA457: Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Formulary NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high grade glioma
Cenegermin 11.99.99.99 Non Formulary NICE TA532: Cenegermin for treating neurotrophic keratitis
Ceritinib 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Ceritinib 08.01.05 Formulary NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Formulary NICE TA 415 Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Cetuximab 08.01.05 Formulary NICE TA242: TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Cetuximab 08.01.05 Formulary NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab 08.01.05 Formulary NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA118: Colorectal cancer (metastatic) - bevacizumab & cetuximab
Cetuximab 08.01.05 Formulary NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Non Formulary NICE TA242:Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy:
Cetuximab 08.01.05 Non Formulary NICE TA172:Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck
Ciclosporin 10.01.03 Formulary NICE CG79 : Rheumatoid Arthritis
Ciclosporin 0.1% eye drops 11.08.01 Formulary NICE TA 369 Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117: Hyperparathyroidism - cinacalcet
Cisplatin 08.01.05 Formulary Pemetrexed maintenance treatment following induction therapy with pemetrexed and cisplatin for non-squamous non-small-cell lung cancer
Cladribine 08.02.04 Formulary NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
Clomifene Citrate 06.05.01 Formulary NICE Clinical Guideline 156 Fertility problems: assessment and treatment
Clopidogrel 02.09 Formulary NICE CG94: unstable angina and NSTEMI
Clopidogrel 02.09 Formulary NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Clozapine tablets 04.02.01 Formulary NICE CG178: psychosis and schizophrenia in adults, treatment and management.
Cobimetinib hemifumarate 08.01.05 Non Formulary NICE TA 414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Colistimethate inhaler 05.01.07 Formulary NICE TA276: colistimethate sodium and tobramycin dry powder for inhalation for treating pseudomonas lung infection in cystic fibrosis
Collagenase 10.03.01 Formulary NICE TA459 Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib 08.01.05 Formulary NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for prevention of stroke and systemic embolism in atrial fibrillation
Dabigatran 02.08.02 Formulary NICE TA157: Dabigatran for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA327 - Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 02.08.02 Formulary NICE TA 157: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabigatran 02.08.02 Formulary NICE TA 249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation
Dabigatran 02.08.02 Formulary NICE TA 327:Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabrafenib 08.01.05 Formulary NICE TA:321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Dabrafenib 08.01.05 Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Dalteparin 02.08.01 Formulary NICE CG144: Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing.
Dalteparin 02.08.01 Formulary NICE CG144: Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing.
Dalteparin 02.08.01 Formulary NICE CG 92 Venous thromboembolism: reducing the risk
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Daratumumab 08.01.05 Formulary NICE TA454: Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)
Daratumumab 08.01.05 Formulary NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Darbepoetin 09.01.03 Formulary NG8 - Anaemia management in chronic kidney disease (Previously -NICE CG114)
Dasabuvir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Degarelix 08.03.04.02 Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 120mg 06.06.02 Formulary NICE TA265: denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours.
Denosumab 60mg 06.06.02 Formulary NICE TA204: denosumab for the prevention of osteoporotic fractures in postmenopausal women.
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA460 Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion
Dexamethasone intravitreal implant 11.04.01 Formulary NICE TA 349 Dexamethasone intravitreal implant for treating diabetic macular oedema
Dexamfetamine 04.04 Formulary NICE NG87: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
Dimethyl fumarate 13.05.02 Formulary NICE TA475 Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dipyridamole MR capsules 02.09 Formulary NICE TA210:Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
Docetaxel 08.01.05 Formulary NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.05 Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Doxorubicin Hydrochloride 08.01.02 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Formulary NICE TA197: Dronedarone for the treatment of non-permanent atrial fibrillation
Dupilumab 13.05.03 Formulary NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Edoxaban 02.08.02 Formulary NICE TA 355: Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA 354: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Edoxaban 02.08.02 Formulary NICE TA 354 Edoxaban for DVT and PE
Edoxaban 02.08.02 Formulary NICE TA 355 Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA355:Edoxaban for preventing stroke and systemic embolism in people with non-valvular atrial fibrillation
Elbasvir with Grazoprevir 05.03.03.02 Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Elotuzumab 08.01.05 Non Formulary Elotuzumab for previously treated multiple myeloma
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
Eluxadoline 01.04.02 Formulary NICE TA471 eluxadoline for treating irritable bowel syndrome with diarrhoea for adults whose condition has not responded to other currently available treatments, or when these treatments are contraindicated or not tolerated
Empagliflozin 06.01.02.03 Formulary NICE TA 336 - Empagliflozin in combination therapy for treating type 2 diabetes
Enoxaparin 02.08.01 Formulary NICE CG144: Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing
Entecavir 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic): diagnosis and management
Entecavir 05.03.03.01 Formulary NICE TA153: Entecavir for the treatment of chronic hepatitis B
Enzalutamide 08.03.04.02 Formulary Enzalutamide for metastatic hormonerelapsed prostate cancer previously treated with a docetaxel]containing regimen (TA316)
Enzalutamide 08.03.04.02 Formulary NICE TA 377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Eribulin 08.01.05 Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens (replaces TA250)
Eribulin 08.01.05 Formulary NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen (not recommended)
Erlotinib 08.01.05 Formulary NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Erlotinib 08.01.05 Formulary NICE TA227: Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (not recommended)
Erlotinib 08.01.05 Formulary NICE374: Erlotinib and Gefitinib for the treatment of non-small-cell lung cancer that has progressed after prior chemotherapy (previously TA162)
Erlotinib 08.01.05 Non Formulary NICE TA227: Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy)
Etanercept 13.05.03 Formulary NICE TA103: etanercept and efalizumab for the treatment of adults with psoriasis.
Etanercept 10.01.03 Formulary NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept 10.01.03 Formulary NICE TA375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Etanercept 10.01.03 Formulary NICE TA383:TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Etelcalcetide 09.05.01.02 Formulary NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.01.05 Formulary NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Evolocumab 02.12 Formulary NICE TA394 Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exemestane 08.03.04.01 Formulary Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy (TA295)
Exemestane 08.03.04.01 Formulary NICE TA112:Hormonal therapies for the adjuvant treatment of early oestrogen-receptor-positive breast cancer
Exenatide prolonged release 06.01.02.03 Formulary NICE NG28: Type 2 diabetes in adults
Exenatide prolonged release 06.01.02.03 Formulary NG28: exenatide prolonged-release suspension for injection in combination with oral antidiabetic therapy for the treatment of type 2 diabetes (Previously NICE TA248)
Exenatide standard release injection 06.01.02.03 Formulary NICE NG28: Type 2 diabetes: management
Ezetimibe 02.12 Formulary NICE TA 385: Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia
Faecal Microbiota Transplant 05.06 Restricted Use NICE IPG485: Faecal microbiota transplant for recurrent Clostridium difficile infection
Febuxostat 10.01.04 Non Formulary NICE TA164: Hyperuricaemia - febuxostat
Febuxostat 10.01.04 Formulary NICE TA164: Febuxostat for the management of hyperuricaemia in people with gout
Fidaxomicin 05.01.07 Restricted Use NICE Evidence summary ESNM1: Clostridium difficile infection: fidaxomicin
Finasteride 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms: quick reference guide
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fluocinolone acetonide intravitreal implant 11.04.01 Formulary NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271)
Fluorouracil 08.01.03 Formulary Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer
Fluticasone furoate & vilanterol 03.02 Formulary NICE Evidence Summary [ESNM34]
Fulvestrant 08.03.04.01 Non Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer (not recommended)
Fulvestrant 08.03.04.01 Non Formulary NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer (not recommended)
Gefitinib 08.01.05 Formulary NICE TA374: Gefitinib and erlotinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy (previously TA175) (not recommended)
Gefitinib 08.01.05 Formulary NICE TA192: gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell-lung cancer
Gemcitabine 08.01.03 Formulary NICE NG85: Pancreatic cancer in adults: diagnosis and management
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Gemcitabine 08.01.03 Formulary Bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer
Gemcitabine 08.01.03 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (not recommended)
Gemtuzumab ozogamicin 08.01.05 Formulary NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Glatiramer Acetate 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Glecaprevir with Pibrentasvir 05.03.03.02 Formulary NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Glucosamine 10.01.05 Non Formulary NICE ’Do not do recommendation’
Golimumab 10.01.03 Formulary NICE TA220: golimumab for the treatment of psoriatic arthritis
Golimumab 10.01.03 Formulary NICE TA383: TND-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis (previously NICE TA233)
Golimumab 10.01.03 Formulary NICE TA 375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA 497 Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 01.05.03 Formulary NICE TA 329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
Guselkumab 13.05.03 Formulary NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Holoclar® 11.99.99.99 Restricted Use NICE TA 467: Holoclar for treating limbal stem cell deficiency after eye burns
Human Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Human Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: routine antenatal anti-D prophylaxis for women who are rhesus D negative
Hyaluronic acid 10.03.01 Non Formulary NICE CG177: Osteoarthritis - care and management in adults
Hydroxychloroquine 13.05.03 Formulary NICE CG79 : Rheumatoid Arthritis
Ibandronic Acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Ibandronic Acid 06.06.02 Formulary NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ibandronic Acid 06.06.02 Formulary TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Ibrutinib 08.01.05 Formulary NICE TA429:Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Ibrutinib 08.01.05 Formulary NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibrutinib 08.01.05 Formulary NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 08.01.05 Non Formulary NICE TA437: Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy
Idelalisib 08.01.05 Formulary NICE TA 359: Idelalisib for treating chronic lymphocytic leukaemia
Idelalisib 08.01.05 Formulary NICE TA 469: Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal)
Iloprost injection 02.05.01 Formulary NICE review of evidence
Imatinib 08.01.05 Formulary NICE TA70: guidance on the use of imatinib for chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (Previously NICETA196)
Imatinib 08.01.05 Formulary NICE TA209: Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Imatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Imatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Imatinib 08.01.05 Non Formulary NICE TA 209 Imatinib for the treatment of unresectable and/or metastatic gastrointestinal stromal tumours
Indapamide 02.02.01 Formulary NICE CG127: Hypertension in adults: diagnosis and management
Infliximab 10.01.03 Formulary NICE TA195: adalimumab, etanercept, infliximab, rituximab and abtacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Infliximab 10.01.03 Formulary NICE TA199: etanercept inflximab and adalimumab for treatment of psoriatic arthritis
Infliximab 10.01.03 Formulary NICE TA 375 Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA130: Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis
Infliximab 10.01.03 Formulary NICE TA 383 (Previously NICE TA143): TNF-alpha inhibitors for ankylosing spondylitis and non radiographic axial spondyloarthritis
Infliximab 01.05.03 Formulary NICE TA 163 - Infliximab for acute exacerbations of ulcerative colitis
Infliximab 01.05.03 Formulary NICE TA 329 - Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262)
Infliximab 01.05.03 Formulary NICE TA 187 - Infliximab (review) and adalimumab for the treatment of Crohn’s disease
Infliximab 13.05.03 Formulary NICE TA 134 - Infliximab for the treatment of adults with psoriasis
Inotuzumab ozogamicin 08.01.05 Formulary NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Insulin (continuous subcutaneous infusion or CSII) 06.01.01 Non Formulary NICE TA151 CSII for the treatment of diabetes mellitus
Insulin Glargine 06.01.01.02 Formulary NG17 (previously NICE TA 53): Type 1 diabetes in adults: diagnosis and management
Interferon Alfa 08.02.04 Formulary NICE TA96: Adefovir and peginteferon alfa-2a for the treatment of chronic hepatitis B.
Interferon Alfa 08.02.04 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C.
Interferon Beta-1a & Interferon Beta 1-b 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for untreated advanced (unresectable or metastatic) melanoma
Ispaghula Husk 01.06.01 Formulary NICE CG 61 Irritable Bowel Syndrome (IBS)
Ispaghula Husk 01.06.01 Formulary NICE CG 99 Constipation in children and young people
Ispaghula Husk 01.06.01 Non Formulary NICE CG61 Irritable Bowel Syndrome
Ispaghula Husk 01.06.01 Non Formulary NICE CG 99 Constipation in children and young people
Ivabradine 02.06.03 Formulary NICE TA267: ivabradine for treating chronic heart failure
Ivabradine 02.06.03 Formulary NICE CG126: management of stable angina
Ixazomib 08.01.05 Formulary NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab 13.05.03 Formulary NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ixekizumab 13.05.03 Formulary NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Lamivudine 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic): diagnosis and management
Lamivudine 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic)
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Leflunomide 10.01.03 Formulary NICE CG79 : Rheumatoid Arthritis
Lenalidomide 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide 08.02.04 Formulary NICE TA171: lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Lenvatinib 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lenvatinib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Lesinurad 10.01.04 Non Formulary NICE TA506: Lesinurad for treating chronic hyperuricaemia in people with gout
Liraglutide 06.01.02.03 Formulary NG28 (previously NICE TA203): type 2 diabetes in adults : management
Lisdexamfetamine 04.04 Formulary NICE NG 87: Attention deficit hyperactivity disorder: diagnosis and management
Lubiprostone 01.06.07 Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lutetium (177Lu) oxodotreotide 08.01.05 Formulary TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
Mannitol 03.07 Formulary NICE TA266: Mannitol dry powder for inhalation for treating cystic fibrosis
Mepolizumab 03.04.02 Restricted Use NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Methylnaltrexone 01.06.06 Non Formulary NICE TA 468: Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal)
Methylphenidate 04.04 Formulary NICE NG87: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents
Methylprednisolone 06.03.02 Formulary NICE CG186 (previously CG8): Multiple Sclerosis; management in primary and secondary care.
Midostaurin 08.01.05 Formulary NICE TA523: Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Formulary NICE TA235: Osteosarcoma - mifamurtide
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Naftidrofuryl Oxalate 02.06.04 Formulary NICE CG147: Lower limb peripheral arterial disease management
Naftidrofuryl Oxalate 02.06.04 Formulary NICE TA223: Intermittent claudication drugs
Naloxegol 01.06.07 Formulary NICE TA 345 Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Formulary NICE TA115: Naltrexone for the management of opioid dependence
Naltrexone-bupropion 04.05.02 Non Formulary NICE TA494 Naltrexone–bupropion for managing overweight and obesity
Natalizumab 08.02.04 Formulary NICE TA127: Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis
Necitumumab 08.01.05 Non Formulary NICE TA 411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Nilotinib 08.01.05 Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nilotinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nintedanib 03.11 Formulary NICE TA379 Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.01.05 Formulary NICE TA 347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Nintedanib 08.01.05 Formulary NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Niraparib 08.01.05 Formulary NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab 08.01.05 Non Formulary NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Nivolumab 08.01.05 Formulary NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nivolumab 08.01.05 Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.01.05 Formulary NIVE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab 08.01.05 Formulary NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 08.01.05 Formulary NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.01.05 Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Obeticholic acid 01.09.01 Restricted Use NICE TA443: Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 08.02.03 Formulary NICE TA 343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Obinutuzumab 08.02.03 Formulary NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Ocriplasmin 11.08.02 Formulary NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Formulary NICE TA 344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Ofatumumab 08.02.03 Non Formulary NICE TA 470: Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal)
Ofatumumab 08.02.03 Non Formulary NICE TA202: Ofatumumab in chronic lymphocytic leukaemia
Olaparib 08.01.05 Formulary NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Olaratumab 08.01.05 Formulary NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Omalizumab 13.05.03 Formulary NICE TA339 Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab 03.04.02 Formulary NICE TA278: omalizumab for treating severe persistent allergic asthma (review of TA133 + TA201)
Ombitasvir with Paritaprevir and Ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Orlistat 04.05.01 Formulary NICE CG43: Obesity prevention
Oseltamivir 05.03.04 Formulary NICE TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza
Oseltamivir 05.03.04 Formulary NICE TA158. oseltamavir, amantadine (review) and zanamavir for the prophylaxis of influenza
Osimertinib 08.01.05 Formulary NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary Bevacizumab in combination with oxaliplatin and either fluorouracil plus folinic acid or capecitabine for the treatment of metastatic colorectal cancer (TA212)
Oxaliplatin 08.01.05 Formulary Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy (TA307)
Oxaliplatin 08.01.05 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Formulary NICE TA284: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA108: Paclitaxel for the adjuvant treatment of early node-positive breast cancer
Paclitaxel - Albumin Bound Formulation (Nab-paclitaxel) 08.01.05 Formulary NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Palbociclib 08.01.05 Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab 08.01.05 Formulary NICE TA242: Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy (not recommended)
Panitumumab 08.01.05 Formulary NICE TA439:Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panitumumab 08.01.05 Formulary NICE TA240: Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)
Panitumumab 08.01.05 Non Formulary NICE TA240: Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)
Panitumumab 08.01.05 Non Formulary NICE TA242:Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy:
Panobinostat 08.01.05 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib 08.01.05 Formulary NICE TA215: pazopanib for the first line treatment of advanced renal cell carcinoma
Pegaptanib 11.08.02 Non Formulary NICE TA155: guidance on pegaptanib in AMD (August 2008)
Pegaspargase 08.01.05 Formulary NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE CG 165: Hepatitis B (chronic) updates and replaces TA96
Peginterferon Alfa 08.02.04 Formulary NICE TA96: adefovir, dipoxivin and peginterferon alfa2a for chronic hepatitis B
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pegylated Irinotecan Hydrochloride 08.01.05 Non Formulary NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Pembrolizumab 08.01.05 Formulary NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pembrolizumab 08.01.05 Formulary NICE TA 357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA 366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA522: Pembrolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab 08.01.05 Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Formulary NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pemetrexed 08.01.03 Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Pemetrexed 08.01.03 Formulary NICE TA124: Lung cancer (non-small-cell) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Penicillamine 10.01.03 Formulary NICE CG79 : Rheumatoid Arthritis
Perampanel 04.08.01 Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Peristeen® 01.05 Formulary NICE MTG36: Peristeen transanal irrigation system for managing bowel dysfunction
Pertuzumab 08.01.05 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab 08.01.05 Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pioglitazone 06.01.02.03 Formulary NICE NG28: Type 2 diabetes in adults: management
pirfenidone 20 Non Formulary NICE TA282: Idiopathic pulmonary fibrosis - pirfenidone
Pirfenidone 03.11 Restricted Use NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma
Pomalidomide 08.02.04 Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Formulary NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Formulary NICE TA317 Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (previously NICE TA182)
Pregabalin 04.03.04 Formulary NICE CG113: Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: Management in primary, secondary and community care
Prucalopride 01.06.07 Formulary NICE TA 211 Prucalopride for the treatment of chronic constipation in women
Quetiapine 04.02.01 Formulary NICE CG178: psychosis and schizophrenia in adults treatment and management
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Raltitrexed 08.01.03 Formulary NICE CG131: Colorectal cancer: diagnosis and management
Ramucirumab 08.01.05 Non Formulary NICE TA 403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ranibizumab 11.08.02 Formulary NICE TA283: ranibizumab for treatment of visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranibizumab 11.08.02 Formulary NICE TA155:Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranibizumab 11.08.02 Formulary NICE TA298: ranibizumab for treatment of choroidal neovascularisation associated with pathological myopia
Ranibizumab 11.08.02 Formulary NICE TA274: Macular oedema (diabetic) - ranibizumab
Ranolazine 02.06.03 Formulary NICE CG126: Stable Angina:Management
Recombinant human erythropoietins 09.01.03 Formulary Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (NICE TA323)
Regorafenib 08.01.05 Formulary NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Regorafenib 08.01.05 Non Formulary NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma
Reslizumab 03.04.02 Restricted Use NICE TA479: Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Formulary NICE TA232: Retigabine for the adjunctive treatment of partial onset seizures in epilepsy
Ribavirin 05.03.03.02 Formulary NICE TA75: interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Ribavirin 05.03.03.02 Formulary NICE TA106:peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Ribavirin 05.03.03.02 Formulary NICE TA200:peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Ribociclib 08.01.05 Formulary NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin 05.01.07 Formulary NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole 04.09.03 Formulary NICE TA20: Guidance on the use of Riluzole (Rilutek) for the treatment of Motor neurone disease
Risedronate 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Risperidone 04.02.01 Formulary NICE CG178: psychosis and schizophrenia in adults treatment and management
Rituximab 10.01.03 Formulary NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rituximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rituximab 08.02.03 Formulary NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Rivaroxaban 02.08.02 Formulary NICE TA287: rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA261: rivaroxaban for the treatment of DVT and prevention of recurrent DVT and PE
Rivaroxaban 02.08.02 Formulary NICE TA170: rivaroxaban for the prevention of VTE after total hip or total knee replacement in adults
Rivaroxaban 02.08.02 Formulary NICE TA335 The use of rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Formulary NICE TA 170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivaroxaban 02.08.02 Formulary NICE TA 261: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Formulary NICE TA 287:Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA 256: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Formulary NICE TA 335: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Rivaroxaban 02.08.02 Formulary NICE TA256: Rivaroxaban for the prevention of stroke and systemic embolism in people with AF
Roflumilast 03.03.03 Formulary NICE TA 461 Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib 08.01.05 Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril valsartan 02.05 Formulary NICE TA388 Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab 10.01.03 Formulary NICE TA 485 Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 13.05.03 Formulary NICE TA350 Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab 10.01.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 10.01.03 Formulary NICE TA 445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Sertraline 04.03.03 Formulary NICE advice:First Choice Antidepressant Use in Adults with Depression or Generalised Anxiety Disorder
Simeprevir 05.03.03.02 Non Formulary NICE TA 331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Sirolimus 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Sirolimus 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Sitagliptin 06.01.02.03 Formulary NICE NG28. Type 2 diabetes in adults: management
Sodium Aurothiomalate 10.01.03 Formulary NICE CG79 : Rheumatoid Arthritis
Sofosbuvir 05.03.03.02 Formulary NICE TA 330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir with ledipasvir 05.03.03.02 Formulary NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Sofosbuvir with velpatasvir 05.03.03.02 Formulary NICE TA431: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Sofosbuvir with Velpatasvir and Voxilaprevir 05.03.03.02 Formulary NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin (growth hormone) 06.05.01 Formulary NICE TA64: Human growth hormone (somatropin) in adults with human growth hormone deficiency
Somatropin (growth hormone) 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children
Sorafenib 08.01.05 Formulary NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Sorafenib 08.01.05 Formulary Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)
Sorafenib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Sorafenib 08.01.05 Formulary NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sunitinib 08.01.05 Formulary Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma (TA169)
Sunitinib 08.01.05 Formulary Sunitinib for the treatment of gastrointestinal stromal tumours (TA179)
Sunitinib 08.01.05 Formulary Bevacizumab (first-line), sorafenib (first- and second-line), sunitinib (second-line) and temsirolimus (first-line) for the treatment of advanced and/or metastatic renal cell carcinoma (TA178)
Sunitinib 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Sunitinib 08.01.05 Formulary NICE TA178: Renal cell carcinoma (2nd line - not recommended)
Sunitinib 08.01.05 Formulary NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib 08.01.05 Formulary NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Tacrolimus 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Tacrolimus 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Tacrolimus 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Tacrolimus 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Tacrolimus (topical) 13.05.03 Formulary NICE TA82: Tacrolimus and pimecrolimus for atopic eczema
Talimogene laherparepvec 08.01.05 Formulary NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telbivudine 05.03.03.01 Non Formulary NICE TA154: Telbivudine for the treatment of chronic hepatitis B
Temozolomide 08.01.05 Formulary NICE TA23: Temozolomide in recurrent malignant glioma (brain cancer)
Temozolomide 08.01.05 Formulary NICE TA121: Carmustin implants and temozolomide for newly diagnosed glioma
Temsirolimus 08.01.05 Non Formulary NICE TA207: Mantle cell lymphoma (relapsed) - temsirolimus (terminated appraisal)
Temsirolimus 08.01.05 Non Formulary NICE TA178: temsirolimus for first-line treatment of advanced and/or metastatic renal cell carcinoma (not recommended)
Tenofovir alafenamide 05.03.03.01 Non Formulary NICE TA435: Tenofovir alafenamide for treating chronic hepatitis B
Tenofovir Disproxil 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic): diagnosis and management
Teriflunomide 08.02.04 Formulary NICE TA303: Teriflunomide for treating relapsing-remitting MS
Teriparatide 06.06.01 Formulary NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (amended)
Thalidomide 08.02.04 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Ticagrelor 02.09 Formulary NICE TA236: Acute coronary syndromes - ticagrelor
Ticagrelor 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tinzaparin 02.08.01 Formulary NICE CG144: Venous thromboembolic diseases: Diagnosis, management and thrombophilia testing
Tisseel Ready-to-Use® 16.01 Formulary NICE IPG 60
Tivozanib 08.01.05 Formulary NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 05.01.04 Formulary NICE TA276: colistimethate sodium and tobramycin dry powder for inhalation for treating pseudomonas lung infection in cystic fibrosis
Tocilizumab 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
Tocilizumab 10.01.03 Formulary NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib 10.01.03 Formulary NICE TA480 Tofacitinib for moderate to severe rheumatoid arthritis
Tolvaptan 06.05.02 Formulary NICE TA358: Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan 08.01.05 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Topotecan 08.01.05 Formulary NICE TA183: topotecan for the treatment of recurrent and stage IVB cervical cancer
Topotecan 08.01.05 Formulary NICE TA184: topotecan for the treatment of relapsed small-cell lung cancer
Topotecan 08.01.05 Non Formulary NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Total parenteral nutrition (TPN) 09.03 Formulary NICE CG32: Nutrition support in adults
Trabectedin 08.01.05 Non Formulary NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trabectedin 08.01.05 Formulary NICE TA185: trabectedin for the treatment of advanced soft tissue sarcoma
Trabectedin 08.01.05 Formulary NICE TA 389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trametinib 08.01.05 Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Trastuzumab 08.01.05 Formulary NICE TA107: Breast cancer (early) - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab emtansine 08.01.05 Formulary NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trifluridine–tipiracil 08.01.03 Formulary NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab 10.01.03 Formulary NICE TA 340 Ustekinumab for treating active psoriatic arthritis (rapid review of technology appraisal guidance 313)
Ustekinumab 01.05.03 Formulary NICE TA456-Ustekinumab for moderately to severe active crohn’s disease
Ustekinumab 13.05.03 Formulary NICE TA180: Psoriasis - ustekinumab
Varenicline 04.10.02 Formulary NICE TA123: Varenicline for smoking cessation
Vedolizumab 10.01.03 Formulary NICE TA342: Vedolizumab for treating moderately to severe ulcerative colitis
Vedolizumab 01.05.03 Formulary NICE TA 342 Vedolizumab in Ulcerative Colitis
Vedolizumab 01.05.03 Formulary NICE TA 352 Vedolizumab in Crohn’s
Vemurafenib 08.01.05 Formulary NICE TA269: vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma
Venetoclax 08.01.05 Formulary NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Verteporfin 11.08.02 Non Formulary NICE NG82: Age-related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vismodegib 08.01.05 Non Formulary NICE TA489: Vismodegib for treating basal cell carcinoma (not recommended)
Zanamivir dry powder for inhalation 05.03.04 Formulary NICE TA 168: amantadine, oseltamavir and zanamavir for the treatment of influenza
Zanamivir dry powder for inhalation 05.03.04 Formulary NICE TA 158: oseltamavir, amantadine (review) and zanamavir for the prophylaxis of influenza
Zoledronic Acid 06.06.02 Formulary NICE TA464: Bisphosphonates for treating osteoporosis
Zolpidem 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Dorset